Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU8V4S)

Drug Name
Moxifloxacin Drug Info
Synonyms
Avelox; MFX; MXF; MXFX; Vigamox; Avalox (TN); Avelon (TN); Avelox (TN); Moxifloxacin [INN:BAN]; Vigamox (TN); Avelox I.V.; Actira (*Hydrochloride*); Avelox (*Hydrochloride*); (1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid; 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Mycoplasma pneumoniae pneumonia Approved [2]
Peritonitis Approved [2]
Pneumonic plague Approved [2]
Septicemic plague Approved [2]
Staphylococcal pneumonia Approved [2]
Staphylococcus aureus infection Approved [2]
Streptococcal pneumonia Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Pneumonia caused by chlamydia Investigative [2]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [2]
Therapeutic Class
Antibiotics
Cross-matching ID
PubChem CID
152946
ChEBI ID
CHEBI:63611
CAS Number
CAS 151096-09-2
TTD Drug ID
DMU8V4S
VARIDT Drug ID
DR00800
ACDINA Drug ID
D00448

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial DNA gyrase (Bact gyrase)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Grepafloxacin DMGLX0T Chronic bronchitis CA20.1 Approved [4]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [3]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [3]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [3]
Norfloxacin DMIZ6W2 Acute gonococcal cervicitis Approved [3]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [3]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [3]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [6]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Staphylococcus Topoisomerase IV (Stap-coc parC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [3]
Levofloxacin DMS60RB Acute maxillary sinusitis Approved [3]
Gatifloxacin DMSL679 Acute gonococcal cervicitis Approved [3]
Ozenoxacin DM6KZMG Impetigo 1B72 Approved [5]
Sparfloxacin DMB4HCT Bacterial infection 1A00-1C4Z Approved [3]
Gemifloxacin DMHT34O Bacterial infection 1A00-1C4Z Approved [3]
Besifloxacin DMPHXMI Ocular inflammation 9C61.24 Approved [6]
Finafloxacin DMZEONG Urinary tract infection GC08 Approved [7]
Delafloxacin Meglumine DMVTU5Q Acute bacterial skin infection 1C41 Approved [8]
Zabofloxacin DMEY1F3 Pneumonia CA40 Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [3]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [3]

References

1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2 Moxifloxacin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
5 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
9 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.